You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

ImmunoGen climbs on Novartis deal

istockphoto.com

Continue reading below

Shares of Waltham’s ImmunoGen Inc., a biotech firm that develops novel anticancer therapeutics using its antibody-drug conjugate technology, rose on a license deal with Novartis to use the company’s ADC technology to develop anticancer therapeutics. ImmunoGen said the Swiss drug giant would pay an upfront fee plus milestone payments of up to $200 million, with royalties from any approved drugs on top of that. This is the second licensing deal Novartis has to use ImmunoGen’s technology.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com